Comparing commercial pharmacogenetic testing results and recommendations for antidepressants with established CPIC guidelines
IntroductionIncreasingly, pharmacogenetic testing helps providers with medication selection based upon patient-specific DNA results. While several government-funded organizations work towards consensus and standardization for testing and interpretation, compliance to these best practices remains inc...
Saved in:
Main Authors: | Tiffany T. Nguyen (Author), Emili J. W. Leary (Author), Joshua T. Lee (Author), Sanjay K. Shukla (Author), Sara A. Griesbach (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines
by: Heshu Abdullah-Koolmees, et al.
Published: (2021) -
Variability Between Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guidelines and a Commercial Pharmacogenetics Laboratory in Genotype to Phenotype Interpretations For Patients Utilizing Psychotropics
by: Christopher Blazy, et al.
Published: (2022) -
Pharmacogenetics of antidepressants
by: Concetta eCrisafulli, et al.
Published: (2011) -
Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines
by: Lisanne E. N. Manson, et al.
Published: (2020) -
Pharmacogenetics of antidepressant drugs: An update
by: Crisafulli Concetta, et al.
Published: (2014)